chufangao/CTO huggingface dataset:
Clinical trial NCT04352205: Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
Official title: A Phase 2 Evaluation of Daratumumab-Based Treatment in Newly Diagnosed Multiple Myeloma Patients With Renal Insufficiency
Sponsor: Emory University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow accrual
Enrollment: 17.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-05-07
Primary completion date: 2024-01-19
Completion date: 2024-01-19
Plan to share individual participant data: NO
IPD sharing description: Results of the trial and not individual patient data will be shared. The study protocol, consent, and investigator's brochure will be available. The statistical plan is incorporated into the protocol, along with inclusion and exclusion criteria.
Clinical trial NCT04250311: Clinical Trial of Efficacy and Safety of ММН-407 in the Treatment of Influenza in Outpatient Adults
Official title: A Multicenter, Placebo-controlled, Double-blind, Randomized Clinical Trial in Parallel Groups to Evaluate the Efficacy and Safety of ММН-407 in the Treatment of Influenza in Outpatient Adults
Sponsor: Materia Medica Holding (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: SUSPENDED 
Why stopped: Due to the end of the ARVI and influenza season, it was suspended until approximately October 01, 2023
Enrollment: 314.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2019-12-12
Primary completion date: 2024-12-31
Completion date: 2024-12-31
Clinical trial NCT02353143: Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia
Official title: First in Man Study With MEN1112, a CD157 Targeted Monoclonal Antibody, in Relapsed or Refractory Acute Myeloid Leukemia.
Acronym: ARMY
Sponsor: Menarini Group (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The Sponsor accepted the iDSMB recommendation to terminate the study due to evidence of unpredictable liver toxicity and meaningful target engagement not translating into any clinical objective response.
Enrollment: 71.0 (ACTUAL)
Number of arms: 1.0
Start date: 2014-12-31
Primary completion date: 2021-04-09
Completion date: 2021-04-09
Limitations and caveats: Study terminated due to any clinical objective response observed in the patients' study population and under the study procedures implemented in the trial
Clinical trial NCT04230720: Effect of Artificial Tears on Biometry
Official title: Impact of Lubrication With Artificial Tears on Biometry Measurements for Cataract Surgery
Sponsor: Weill Medical College of Cornell University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Stopped due to COVID-19.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-30
Primary completion date: 2021-12-31
Completion date: 2021-12-31
Plan to share individual participant data: NO
Clinical trial NCT03718299: A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis
Official title: An Open-Label, Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Moderate to Severe Plaque Psoriasis
Sponsor: Sun Pharmaceutical Industries Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 55.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-07-16
Primary completion date: 2021-11-02
Completion date: 2021-11-05
Plan to share individual participant data: NO
Clinical trial NCT03348462: Formulation and Clinical Evaluation of Ethosomal and Liposomal Preparations of Anthralin in Psoriasis
Official title: Formulation and Clinical Evaluation of Ethosomal and Liposomal Preparations of Anthralin in Psoriasis
Sponsor: Assiut University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 20.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-11-30
Primary completion date: 2019-12-30
Completion date: 2020-01-15
Clinical trial NCT03923478: ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis
Official title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 1b Study to Evaluate the Safety, Efficacy and Mircobiological Response of Oral ABI-M201 in Subjects With Mildly-to-Moderately Active UC With Ongoing Mesalamine Treatment
Sponsor: Assembly Biosciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor Decision
Enrollment: 15.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-06-24
Primary completion date: 2021-01-20
Completion date: 2021-01-20
Plan to share individual participant data: NO
Clinical trial NCT02526329: Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Transplant
Official title: A Phase 1 Single Center Safety and Feasibility Study of Primary T Regulatory Cell Therapy to Treat Visceral Acute Graft-versus-Host Disease Following Hematopoietic Cell Transplantation
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Logistics
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-08-06
Primary completion date: 2022-11-30
Completion date: 2023-06-30
Plan to share individual participant data: NO
Clinical trial NCT03721679: Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1
Official title: Poly-ICLC (Hiltonol®) Plus Anti-PD1 or Anti-PD-L1 in Unresectable Solid Cancers An Adaptive Phase I/II Clinical Pilot Study
Sponsor: Oncovir, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Recruiting target patients is intermittent making it impracticable to enroll the required study sample. The administrative responsibilities have been met with extraordinary challenges. Current funding does not match the incurring costs.
Enrollment: 7.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-09-25
Primary completion date: 2021-01-26
Completion date: 2021-01-26
Plan to share individual participant data: NO
Clinical trial NCT03000127: Testosterone for Fatigue in Men With MS
Official title: A Pilot Trial of Testosterone Treatment for Fatigue in Men With Multiple Sclerosis
Sponsor: University of California, Los Angeles (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Lack of funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-07-01
Primary completion date: 2023-06-30
Completion date: 2024-01-01
Plan to share individual participant data: NO
Clinical trial NCT03738111: Study of TG02 Citrate in Patients With Advanced Hepatocellular Carcinoma
Official title: A Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hepatocellular Carcinoma
Sponsor: Lee's Pharmaceutical Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Sponsor's commercial decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-12-31
Primary completion date: 2021-08-31
Completion date: 2021-12-31
Plan to share individual participant data: NO
Clinical trial NCT04286529: Effect of 1,25-dihydroxyvitamin D3, Treatment on Insulin Secretion and Muscle Strength in Pre-diabetic Persons
Official title: Effect of 1,25-dihydroxyvitamin D3, Treatment on Insulin Secretion and Muscle Strength in Pre-diabetic Persons
Sponsor: Mayo Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Difficulty with study logistics due to COVID-19
Enrollment: 17.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-10-01
Primary completion date: 2021-05-28
Completion date: 2021-05-28
Plan to share individual participant data: NO
Clinical trial NCT03670030: A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System
Official title: A Pilot Phase 2 Study of Albumin-bound Rapamycin Nanoparticles, ABI-009, in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System
Sponsor: Ochsner Health System (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow enrollment
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-11-05
Primary completion date: 2021-01-01
Completion date: 2021-02-26
Limitations and caveats: Early termination leading to small numbers affecting usefulness interpreting results. Only 2 patients were eligible for analysis of primary outcome.
Plan to share individual participant data: NO
IPD sharing description: Only aggregate data will be made publicly available in the form of poster presentations or journal articles.
Clinical trial NCT01553149: Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
Official title: A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Sponsor: National Cancer Institute (NCI) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 75.0 (ACTUAL)
Number of arms: 2.0
Start date: 2012-07-05
Primary completion date: 2020-06-30
Completion date: 2023-12-31
Clinical trial NCT03546907: Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
Official title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of SAR440340, in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 343.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-07-16
Primary completion date: 2019-10-03
Completion date: 2020-02-21
Baseline population: Randomized population included any participant who had signed informed consent and had been allocated to a randomized treatment regardless of whether the treatment kit was used.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT03435640: REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies
Official title: A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-262 in Combination With Bempegaldesleukin (NKTR-214) With or Without Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies
Acronym: REVEAL
Sponsor: Nektar Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Based on the overall results from the Phase 1 part of the study the sponsor decided to end the study. The decision was not due to safety reasons.
Enrollment: 64.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-03-15
Primary completion date: 2022-05-09
Completion date: 2022-05-09
Plan to share individual participant data: NO
Clinical trial NCT04084678: A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH
Official title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by CPET in Subjects With WHO Group 1 Pulmonary Hypertension Who Recently Initiated Therapy
Acronym: CAPACITY
Sponsor: United Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Sponsor decision
Enrollment: 10.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-01-20
Primary completion date: 2023-04-12
Completion date: 2023-04-12
Clinical trial NCT05016284: Comparison of JW-100 and EUCRISA for the Treatment of Atopic Dermatitis
Official title: A Double-blind, Superiority, and Randomized Controlled Trial to Evaluate the Efficacy of a Novel Cannabidiol Cream for Treatment of Atopic Dermatitis
Sponsor: Applied Biology, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Lack of funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-11-24
Primary completion date: 2022-12-15
Completion date: 2022-12-15
Plan to share individual participant data: NO
IPD sharing description: Data will not be shared
Clinical trial NCT04392362: A Trial to Compare American Heart Association (AHA) and Simple (SIM)Method to Give Adenosine to Treat Supra-ventricular Tachycardia (SVT)
Official title: A Randomised Controlled Trial of the Standard Versus a Simplified Adenosine Administration Method in the Treatment of Adult Patients With Supra- Ventricular Tachycardia (SVT)
Acronym: AHAvsSIM
Sponsor: University of Pretoria (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 30.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-04-01
Primary completion date: 2020-12-16
Completion date: 2020-12-16
Plan to share individual participant data: NO
Clinical trial NCT04793399: Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients
Official title: Multicenter, Open-label, Phase Ib/II Trial to Evaluate Safety and Efficacy for the Combination of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Myeloid Leukemia Patients
Sponsor: Fundacion Espanola para la Curacion de la Leucemia Mieloide Cronica (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The study has been prematurely terminated due to the onset of 2 dose limiting toxicities in 2 patients.
Enrollment: 9.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-02-24
Primary completion date: 2021-09-24
Completion date: 2021-09-24
Clinical trial NCT02230527: Establishing the Microcirculatory Effects of Ticagrelor on Tissue Perfusion in Critical Limb Ischemia
Official title: Establishing the Microcirculatory Effects of Ticagrelor on Tissue Perfusion in Critical Limb Ischemia
Sponsor: The Cleveland Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Lack of enrollment
Enrollment: 46.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-10-31
Primary completion date: 2020-05-31
Completion date: 2020-05-31
Plan to share individual participant data: NO
Clinical trial NCT05038904: Preventing Anaphylaxis With Acalabrutinib
Official title: Preventing Life-Threatening Allergic Reactions With Acalabrutinib, an FDA-Approved Bruton's Tyrosine Kinase Inhibitor
Sponsor: Johns Hopkins University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 10.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-12-16
Primary completion date: 2022-12-08
Completion date: 2022-12-31
Limitations and caveats: Limitations included a small patient population, the lack of fully blinded oral food challenges, and the lack of placebo treatment arm. Additionally, this trial did not investigate alternative durations or dosages of acalabrutinib; therefore, the minimum effective duration and dose are as yet undetermined.
Plan to share individual participant data: NO
Clinical trial NCT03105219: IvaBradinE to Treat MicroalbumiNuria in Patients With Type 2 Diabetes and Coronary Heart Disease
Official title: IvaBradinE to Treat MicroalbumiNuria in Patients With Type 2 Diabetes and Coronary Heart Disease
Acronym: BENCH
Sponsor: Nanjing First Hospital, Nanjing Medical University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Shortfall in funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-07-01
Primary completion date: 2021-05-30
Completion date: 2021-05-30
Plan to share individual participant data: NO
Clinical trial NCT04459767: Investigation Of Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Doses Of Vupanorsen In Japanese Healthy Adult Participants With Elevated Triglycerides
Official title: A PHASE 1, RANDOMIZED, DOUBLE-BLIND, THIRD-PARTY OPEN, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PF-07285557 (VUPANORSEN) ADMINISTERED SUBCUTANEOUSLY IN JAPANESE HEALTHY ADULTS WITH ELEVATED TRIGLYCERIDES
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 12.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-08-06
Primary completion date: 2020-12-15
Completion date: 2020-12-15
Plan to share individual participant data: NO
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT03684785: Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors
Official title: Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors: A Phase 1b/2 Study of Cavrotolimod Combined With Pembrolizumab or Cemiplimab
Sponsor: Exicure, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The study was canceled for administrative reasons.
Enrollment: 57.0 (ACTUAL)
Number of arms: 7.0
Start date: 2018-12-13
Primary completion date: 2022-03-30
Completion date: 2022-03-30
Plan to share individual participant data: YES
IPD sharing description: Individual participant data that underlie the results reported in the article, after de-identification (text, tables, figures, and appendices) will be shared to researchers who provide a methodologically sound proposal and sign a data access agreement.
IPD time frame: Beginning 9 months and ending 36 months following article publication.
IPD access criteria: Access will be considered to researchers who provide a methodologically sound proposal. Analysis must achieve the aims outlined in the approved proposal. Proposals should be directed to edegoma@exicuretx.com. To gain access, data requestors will need to sign a data access agreement. Data are available for 36 months following article publication.
Clinical trial NCT05144334: A Study of BTX-1188 in Subjects With Advanced Malignancies
Official title: An Open Label, Escalating Multiple Dose Study to Evaluate the Safety, Toxicity, Pharmacokinetics, and Preliminary Activity of BTX-1188 in Subjects With Advanced Malignancies
Sponsor: Biotheryx, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Business decision
Enrollment: 8.0 (ACTUAL)
Number of arms: 7.0
Start date: 2022-01-24
Primary completion date: 2023-09-12
Completion date: 2023-09-12
Clinical trial NCT03783702: Pain Control Following Sinus Surgery
Official title: Multi-institutional, Randomized Controlled Trial Assessing Opioid Use and Analgesic Requirements After Endoscopic Sinus Surgery
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 118.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-04-04
Primary completion date: 2020-07-01
Completion date: 2020-12-30
Limitations and caveats: The low levels of narcotic consumption observed may have precluded achieving significance in pain score comparisons across groups, as the pre-hoc power analysis predicted higher levels of opioid use~Selection bias: 1) patient willingness to participate in an opioid-related study could serve as a source of bias 2) loss to follow up~Lack of blinding and placebo were additional limitations
Plan to share individual participant data: NO
Clinical trial NCT03355664: Study to Compare the Triple ACT AL+AQ With the ACT AL in Cambodia and Vietnam
Official title: A Multi-centre, Open-label Randomised Trial to Assess the Efficacy, Safety and Tolerability of the Triple ACT Artemether-lumefantrine+Amodiaquine (AL+AQ) Compared to the ACT Artemether-lumefantrine (AL) in Uncomplicated Falciparum Malaria in Cambodia and Vietnam
Acronym: TACT-CV
Sponsor: University of Oxford (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 310.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-03-19
Primary completion date: 2020-03-04
Completion date: 2020-03-04
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04198818: A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors
Official title: A First-in-Human, Open Label, Phase I/II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patients With Advanced Tumors
Sponsor: Haihe Biopharma Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Sponsor business decision
Enrollment: 37.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-01-07
Primary completion date: 2023-03-31
Completion date: 2023-03-31
Plan to share individual participant data: NO
Clinical trial NCT04941443: Methadone and Medication Abortion
Official title: Methadone for Pain Relief in First Trimester Medication Abortion
Sponsor: Boston Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Inability to recruit more participants.
Enrollment: 4.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-10-04
Primary completion date: 2022-03-01
Completion date: 2022-03-01
Limitations and caveats: The study was halted prematurely as it was very difficult to recruit participants. Of the 4 consented participants, none provided the information needed for any of the outcome measures, so no results are available.
Plan to share individual participant data: NO
Clinical trial NCT03737240: IDegLira HIGH Trial
Official title: A Randomized Controlled Trial Comparing the Safety and Efficacy of IDegLira Versus Basal Bolus in Patients With Poorly Controlled Type 2 Diabetes
Sponsor: Emory University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 145.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-15
Primary completion date: 2022-07-08
Completion date: 2022-07-08
Clinical trial NCT04213573: Efficacy of Silver Diamine Fluoride and Its Parental Perception
Official title: Parental Perception of Silver Diamine Fluoride Staining and Its Efficacy on Caries Arrestment in Comparison to Sodium Fluoride With Casein Phosphopeptide-amorphous Calcium Phosphate
Sponsor: University of Baghdad (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: SUSPENDED 
Why stopped: because of corona virus epidemic
Enrollment: 60.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2020-01-21
Primary completion date: 2020-10-20
Completion date: 2020-12-20
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03652623: Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - PK Study
Official title: Transgender Youth and PrEP: PK, Safety, Uptake & Adherence
Sponsor: Hektoen Institute for Medical Research (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 49.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-07-23
Primary completion date: 2023-11-30
Completion date: 2023-11-30
Plan to share individual participant data: NO